Zydus Wellness Ltd logo

Zydus Wellness Ltd

ZYDUSWELL NSE

Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Source : 202003 Annual Report Page No: 83)

AI Verdict: HOLD Confidence: 4%

Zydus Wellness has strong revenue momentum with TTM sales growth of 46% and overwhelming analyst buy ratings (86%), but a PE of 81.3x with declining profits (-30% TTM) and ROE of just 4-5% make the valuation hard to justify at current levels.

Key Fundamentals

Volatility
Moderate
P/E Ratio
83.56
EBITDA
₹448 Cr
Return on Equity
4.98%
Debt to Equity
0.05
EPS
₹47.81
52W High
₹552.4
52W Low
₹367.55

Technical Indicators

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

5
  • Stock is trading at 2.86 times its book value
  • Tax rate seems low
  • Company has a low return on equity of 5.11% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 14.1% of profits over last 3 years

Growth Rate

Revenue Growth
44.72% ↘
Net Income Growth
-42.38% ↘
Cash Flow Change
54.22% ↗
ROE
22.89% ↗
ROCE
23.30% ↗
EBITDA Margin (Avg.)
-21.45% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
HOLD
Risk high

Zydus Wellness has strong revenue momentum with TTM sales growth of 46% and overwhelming analyst buy ratings (86%), but a PE of 81.3x with declining profits (-30% TTM) and ROE of just 4-5% make the valuation hard to justify at current levels.

Bull Case 7
  • TTM revenue growth of 46% indicates significant top-line acceleration, well above the 5-year CAGR of 16%
  • 86% analyst buy consensus (6 out of 7 analysts) with zero sell ratings signals strong institutional confidence
  • Stock CAGR of 28% over 1 year shows strong price momentum and market re-rating
  • 3-year sales CAGR of 21% demonstrates consistent double-digit revenue compounding
  • 10-year sales CAGR of 26% reflects a long-term structural growth story in the FMCG space
  • Market cap of Rs 16,093 Cr positions the company as a mid-cap with room for re-rating if profitability improves
  • Company is expected to deliver a good upcoming quarter per screener consensus
Bear Case 8
  • PE ratio of 81.3x is extremely elevated for an FMCG company delivering negative profit growth, implying the stock prices in years of flawless execution
  • TTM profit decline of -30% is alarming and diverges sharply from 46% revenue growth, suggesting severe margin compression
  • 3-year ROE of just 5% and last year ROE of 4% are far below the 15-20% typically expected from quality FMCG businesses
  • 5-year profit CAGR of -2% means the company has destroyed earnings power over a half-decade horizon despite revenue growth
  • Dividend payout of only 14.1% of profits over 3 years with a yield of 0.24% offers negligible income return to shareholders
  • Price-to-book of 2.75x combined with sub-6% ROE means the company is not generating adequate returns on its asset base to justify the premium
  • Potential interest cost capitalization raises questions about the true profitability and quality of reported earnings
  • Low tax rate flagged as a concern may indicate one-off benefits that could reverse, further pressuring future net profits

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Positives 4
  • Dubai subsidiary for expansion Jun 24

    Zydus Wellness Trading L.L.C. incorporated in Dubai on Jun 24 with AED 300,000 share capital, targeting food, nutrition, and personal care business expansion in the UAE.

  • EU subsidiary in Ireland Jun 23

    Zydus Wellness (EU) Limited incorporated in Ireland on Jun 23 with €100 share capital, signaling intent to build a European presence.

  • Promoter buying in open market Jun 16

    Promoter group member Samar Babubhai Patel acquired 500 shares on Jun 12 via NSE open market; separately, Rupa Parekh acquired 4,000 shares worth ₹19.9 lakh on Jun 1.

  • Hong Kong investor roadshow Jun 22

    Non-deal roadshow scheduled in Hong Kong on Jun 25, indicating active engagement with international institutional investors.

Neutral 2
  • ICICI conference participation Jun 2

    Zydus Wellness participated in the ICICI Securities India Investor Conference on Jun 8 in Mumbai.

  • Promoter shares via transmission May 26

    Samar Babubhai Patel received 10,000 shares via transmission from Late Jasodaben Babubhai Patel, a routine intra-family transfer with no market impact.

TL;DR: Zydus Wellness is actively pursuing international expansion with new subsidiaries in Dubai and Ireland, and engaging global investors through roadshows. Promoter group members are adding to their holdings via open market purchases, a mild confidence signal. No material headwinds have emerged in recent weeks. The trend is constructive, with the company positioning itself for broader geographic reach in food and personal care.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
713
702
440
403
783
841
493
462
913
861
650
965
1,485
Expenses
568
586
423
390
620
686
473
447
723
705
628
904
1,215
Operating Profit
145
116
17
13
162
155
20
15
190
156
23
61
270
OPM %
20%
17%
4%
3%
21%
18%
4%
3%
21%
18%
4%
6%
18%
Other Income
-6
-12
4
3
4
5
10
4
1
3
-33
-6
1
Interest
5
5
6
6
6
4
1
3
4
2
16
41
39
Depreciation
7
6
6
6
6
5
5
5
13
11
25
56
55
PBT
126
93
9
4
154
152
24
10
173
145
-51
-42
177
Tax %
-15%
-18%
31%
92%
3%
3%
12%
37%
1%
12%
4%
-4%
9%
Net Profit
145
110
6
0
150
148
21
6
172
128
-53
-40
162
EPS in Rs
4.57
3.47
0.19
0.01
4.72
4.64
0.66
0.2
5.4
4.02
-1.66
-1.25
5.09
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
431
397
431
513
843
1,767
1,867
2,009
2,255
2,328
2,709
3,961
Expenses
331
305
331
387
658
1,446
1,522
1,664
1,918
2,020
2,329
3,451
Operating Profit
100
91
99
125
185
321
344
345
337
308
380
510
OPM %
23%
23%
23%
24%
22%
18%
18%
17%
15%
13%
14%
13%
Other Income
28
32
32
35
28
-33
-123
10
-5
0
19
-34
Interest
0
0
1
2
30
140
84
26
16
24
12
98
Depreciation
8
7
7
9
13
26
25
24
25
24
28
147
PBT
120
117
124
150
171
121
112
306
291
260
359
230
Tax %
7%
10%
10%
9%
0%
-17%
-6%
-1%
-7%
-3%
3%
14%
Net Profit
111
105
111
137
171
142
119
309
310
267
347
197
EPS in Rs
5.58
5.28
5.58
6.85
5.87
4.92
3.73
9.71
9.75
8.39
10.9
6.2
Div. Payout %
22%
25%
23%
23%
17%
20%
27%
10%
10%
12%
11%
19%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
39
39
39
39
58
58
64
64
64
64
64
64
Reserves
367
439
518
652
3,329
3,403
4,504
4,780
5,059
5,294
5,608
5,762
Borrowings
0
0
25
25
1,569
1,519
550
387
297
329
188
3,203
Other Liabilities
102
89
100
112
503
610
548
461
413
462
582
1,279
Total Liabilities
508
568
682
829
5,459
5,590
5,666
5,692
5,833
6,148
6,442
10,308
Fixed Assets
84
82
103
104
4,567
4,674
4,667
4,710
4,732
4,708
5,125
8,596
CWIP
0
0
0
0
10
4
4
12
13
10
15
23
Investments
0
94
30
148
46
110
0
27
70
78
36
5
Other Assets
423
391
550
577
835
802
995
943
1,018
1,354
1,266
1,684
Total Assets
508
568
682
829
5,459
5,590
5,666
5,692
5,833
6,148
6,442
10,308
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
69
90
77
69
149
259
287
237
92
246
380
226
Investing
29
-28
-72
-59
-4,092
-17
-10
-59
-85
-178
-207
-2,910
Financing
-27
-58
-6
-2
4,052
-260
-216
-234
-138
-26
-186
2,698
Net Cash Flow
71
4
-1
8
109
-18
60
-56
-132
43
-13
15
Free Cash Flow
72
86
46
61
132
235
269
162
47
220
315
126
CFO/OP
80
114
86
64
115
81
83
70
28
81
99
50
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
1
3
3
6
42
24
18
26
34
44
49
35
Inventory Days
76
73
127
113
393
168
158
135
146
150
148
178
Days Payable
146
191
264
254
662
289
189
136
100
116
122
107
Cash Conversion Cycle
-69
-116
-134
-135
-227
-97
-13
25
80
78
75
106
Working Capital Days
-37
-38
-57
-26
-26
-7
-35
-27
17
20
34
49
ROCE %
32%
26%
23%
22%
7%
6%
6%
6%
6%
5%
6%
5%

Shareholding Pattern

As of Mar 2026
Promoters 69.64%
DIIs 18.87%
Public 8.32%
FIIs 3.17%
Total 100.00%
  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
67.11%
68.54%
69.15%
69.62%
69.62%
69.62%
69.62%
69.64%
69.64%
69.64%
69.64%
69.64%
FIIs
3.23%
3.42%
3.25%
3.26%
3.29%
3.36%
3.37%
3.29%
3.25%
3.43%
3.27%
3.17%
DIIs
22.04%
20.22%
19.67%
19.41%
19.44%
20.37%
20.12%
19.76%
19.27%
18.76%
18.58%
18.87%
Public
7.62%
7.81%
7.91%
7.71%
7.65%
6.67%
6.89%
7.30%
7.83%
8.18%
8.51%
8.32%
No. of Shareholders
73,029
76,590
75,369
69,138
63,973
60,981
64,037
64,979
66,514
77,188
80,105
80,671

Documents

Frequently Asked Questions about Zydus Wellness Ltd

What does Zydus Wellness Ltd do?
Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Sou...
Where is Zydus Wellness Ltd (ZYDUSWELL) listed?
Zydus Wellness Ltd is listed on the Indian stock exchanges. It is listed on NSE: ZYDUSWELL and BSE: 531335. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Zydus Wellness Ltd belong to?
Zydus Wellness Ltd operates in the Food Products sector within the Packaged Foods industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the PE ratio of Zydus Wellness Ltd?
The Price-to-Earnings (PE) ratio of Zydus Wellness Ltd is 83.56. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Zydus Wellness Ltd?
Over the past 52 weeks, Zydus Wellness Ltd has traded between a low of ₹367.55 and a high of ₹552.4. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Zydus Wellness Ltd?
Zydus Wellness Ltd has a Return on Equity (ROE) of 4.98%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Zydus Wellness Ltd on Tapetide?
On Tapetide, you can view Zydus Wellness Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Source : 202003 Annual Report Page No: 83)

Website zyduswellness.in
CEO Mr. Tarun G. Arora
Employees 1,247
Listed 2009-11-13
Face Value ₹ 2
Issued Size 31,81,60,720

Explore More

More in Food Products → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List